Prostate cancer trials undertaken at the University of Sydney have provided exciting results with reductions of up to 25 per cent of tumour growth in mouse models.
Bioengineers at Yale and Cornell have created a modified chemotherapy that more effectively reaches and remains at the site of brain tumors — by adding a water-soluble polymer to the anti-cancer drug, according to a report in the November-December issue of Bioconjugate Chemistry.
Researches at Emory University have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important “intercept points” for cancer cells.
A non-invasive diagnostic tool to detect surface cancers quickly and painlessly using technology currently employed by gyms to calculate body composition has been developed by a QUT PhD medical physics researcher.
A team of investigators from the Massachusetts General Hospital (MGH) BioMicroElectroMechanical Systems (BioMEMS) Resource Center and the MGH Cancer Center has developed a microchip-based device that can isolate, enumerate and analyze circulating tumor cells (CTCs) from a blood sample. CTCs are viable cells from solid tumors carried in the bloodstream at a level of one in a billion cell. Because of their rarity and fragility, it has not been possible to get information from CTCs that could help clinical decision-making, but the new device - called the "CTC-chip,"- has the potential to be an invaluable tool for monitoring and guiding cancer treatment.